

04 FEB 18 (M) 7:21



Office of International Corporate Finance  
Division of Corporate Finance  
Securities and Exchange Commission  
450 Fifth Street  
Washington, D.C. 20549  
U.S.A.

**SUPPL**

February 11, 2004

**SUPPL**

Re: Investor AB – file no 82-34698

The enclosed information is being furnished pursuant to Rule 12g3-2(b). The enclosures are all relevant documents since the date of initial submission on October 30, 2002.

Very truly yours,

Gunilla Swardh  
Compliance Officer

**PROCESSED**

**FEB 26 2004**

**THOMSON  
FINANCIAL**

Enclosures

## Disclosure Notice

Stockholm, February 11, 2004

Investor's share of the voting rights and share capital in AstraZeneca has changed through the divestment of 21,200,000 shares.

After the sale, Investor's holding in AstraZeneca now amounts to 63,465,810 shares corresponding to 3.75 percent of the voting rights and share capital. On December 31, 2003, Investor's holding in AstraZeneca amounted to 5.0 percent of the votes and capital.

In a statement, Investor President and CEO Marcus Wallenberg said: "We have decided to reduce our leverage and strengthen our financial flexibility. We continue to believe strongly in AstraZeneca and the company is still our largest holding."

INVESTOR AB

For further information:

Fredrik Lindgren, Vice President, Corporate Communications:  
+46 8 614 20 31, +46 735 24 20 31

*Our press releases can be accessed at [www.investorab.com](http://www.investorab.com) on the Internet.*

Investor AB is Sweden's largest listed industrial holding company. The company's business concept is to create shareholder value through long-term committed ownership and active investment activities. Investor is a leading shareholder in a number of public multinational companies, including AstraZeneca, Ericsson and SEB. Investor also conducts venture capital activities in North America, Europe and Asia.